Oncolytics Biotech Files October 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Oct 20, 2025 · CIK: 1129928
Sentiment: neutral
Topics: sec-filing, 6-K, foreign-private-issuer
Related Tickers: ONCY
TL;DR
ONCOLYTICS BIOTECH (ONCY) filed its monthly 6-K, standard foreign issuer report.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on October 20, 2025, for the month of October 2025. The company is a foreign private issuer based in Calgary, Alberta, Canada, and is subject to the 1934 Securities Exchange Act. It is filing under the standard industrial classification for Pharmaceutical Preparations.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Oncolytics Biotech Inc.'s ongoing operations and compliance as a foreign private issuer.
Risk Assessment
Risk Level: low — This filing is a routine report for a foreign private issuer and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer of the report
- October 2025 (date) — Reporting period
- 20251020 (date) — Filing date
- Calgary, Alberta, Canada (location) — Company's principal executive offices
- 001-38512 (other) — SEC file number
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of October 2025.
What is the filing date of this report?
The filing date is October 20, 2025.
Where are Oncolytics Biotech Inc.'s principal executive offices located?
The principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
What is the SEC file number for Oncolytics Biotech Inc.?
The SEC file number is 001-38512.
Does Oncolytics Biotech Inc. file annual reports under Form 20-F or Form 40-F?
The filing indicates that the registrant files annual reports under Form 20-F.
Filing Stats: 1,386 words · 6 min read · ~5 pages · Grade level 15.5 · Accepted 2025-10-17 21:54:11
Key Financial Figures
- $50.0 million — ng an aggregate offering price of up to $50.0 million (the “Shares”). The Regist
Filing Documents
- tm2528875d1_6k.htm (6-K) — 22KB
- tm2528875d1_ex1-1.htm (EX-1.1) — 287KB
- tm2528875d1_ex5-1.htm (EX-5.1) — 8KB
- 0001104659-25-100535.txt ( ) — 318KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By: /s/ Kirk Look Kirk Look Date: October 17, 2025 Chief Financial Officer